Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32675289 | 1.00 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2911817 | 0.81 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13066221 | 0.80 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL83318 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29352597 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL440122 | 0.76 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29758335 | 0.76 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28492020 | 0.76 | CYP1A2 (0.44) | ACHECYP1A2CYP2A6ALDH1A1KDM4E | |
| SCHEMBL29096230 | 0.75 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6259011 | 0.74 | CA12 (0.43) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9528979-B2 | Breath analysis of pulmonary nodules | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2016-12-27 | — | — | US | claimed |
| US-20130150261-A1 | BREATH ANALYSIS OF PULMONARY NODULES | TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD. (IL) | 2013-06-13 | — | — | US | claimed |
| US-7332623-B2 | Aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-02-19 | — | — | US | claimed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | claimed |
| US-20050004212-A1 | Aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY | 2005-01-06 | — | — | US | claimed |
| US-20050004211-A1 | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds | KAOHSIUNG MEDICAL UNIVERSITY | 2005-01-06 | — | — | US | claimed |
| US-5290911-A | Forming polymers by catalytic oxidative coupling | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1994-03-01 | — | — | US | claimed |
| US-20240389906-A1 | NON-INVASIVE MONITORING SYSTEM | AERBETIC INC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12036020-B2 | Non-invasive monitoring system | AERBETIC, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20220007972-A1 | NON-INVASIVE MONITORING SYSTEM | AERBETIC, INC. (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3889135-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3675873-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG, LLC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-0617036-A2 | Novel 2-thiosubstituted carbapenems | AMERICAN CYANAMID COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5290911-A | Forming polymers by catalytic oxidative coupling | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1994-03-01 | — | — | US | disclosed |
| US-5153305-A | From diaryl disulfide; mild conditions using organometallic catalyst | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1992-10-06 | — | — | US | disclosed |
| US-4983720-A | Process for preparing a polyarylene thioether | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0402481-A1 | PRODUCTION OF POLYARYLENE THIOETHER | RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) | 1990-12-19 | — | — | EP | disclosed |
| US-4931542-A | Process for preparing a polyarylene thioether | IDEMITSU PETROCHEMICAL COMPANY, LIMITED (JP) | 1990-06-05 | — | — | US | disclosed |
| EP-0281036-A2 | A process for preparing a polyarylene thioether | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004211-A1 | Pharmaceutical compositions comprising aryl-substituted acyclic enediyne compounds | CCNI, TOP1, TOP2B | CA12 1888/4885CA1 2271/4885CA2 918/4885 |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CA12 4761/4885CA1 4833/4885CA2 4689/4885 |
| US-20050004212-A1 | Aryl-substituted acyclic enediyne compounds | CCNI, TOP2B, TOP2A | CA12 3857/4885CA1 3376/4885CA2 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.